Compositions containing an active fraction isolated from tricholoma conglobatum and methods of use

A process for preparing a biologically active fraction ATC07α from a composition of Tricholoma Conglobatum comprising the steps of:

• a) homogenizing an effective amount of Tricholoma Conglobatum in an effective amount of buffer solution and filtering to collect the supernatant;
• b) concentrating the supernatant;
• and
• c) isolating a fraction having an optical absorbance at about 210 nm to about 350 nm.

A process for preparing a biologically active compound ATC07α from a composition of Tricholoma Conglobatum comprising the steps of:

• a) homogenizing an effective amount of Tricholoma Conglobatum in an effective amount of buffer solution and filtering to collect the supernatant;
• b) precipitating the supernatant with an effective amount of ammonium sulfate;
• c) collecting the 35% to 70% ammonium sulfate fraction;
• d) dialyzing against an effective amount of potassium phosphate;
• e) purifying the active fractions by ion exchange column chromatography;
• and
• f) obtaining the active compound by chromatography to obtain a biologically active extract having an optical absorbance from about 210 nm to about 350 mn.

A process for preparing a biologically active compound ATC07β from a composition of Tricholoma Conglobatum comprising the steps of:

• a) homogenizing an effective amount of Tricholoma Conglobatum in an effective amount of buffer solution and filtering to collect the supernatant;
• b) precipitating the supernatant with an effective amount of ammonium sulfate;
• c) collecting the 35% to 70% fraction;
• d) dialyzing against an effective amount of potassium phosphate;
• e) purifying the active fractions by ion exchange column chromatography to obtain the active fractions ACT70β.

A method for screening for a therapeutic agent for inhibiting neovascularization or endothelial cell growth comprising the steps of:

• a) contacting the agent with a suitable cell or tissue sample;
• b) contacting a separate sample of the suitable cell or tissue sample with a therapeutically effective amount of an agent selected from the group consisting of ECTa, ECTb, ATC07α, ATC07β, ATC07β1, and ATC07β2;
• and
• c) comparing the growth of the sample of step (a) with the growth of the sample of step (b), and wherein any agent of step (a) that inhibits the growth to the same or similar extent as the sample of step (b) is a therapeutic agent for inhibiting neovascularization or the growth of endothelial cells.